KAI Pharmaceuticals

Lycera names Paul Sekhri president and CEO

Thursday, February 5, 2015

Lycera, a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, has named Paul Sekhri president, CEO and a member of the board of directors, effective immediately. Sekhri brings more than 25 years of operational experience in the life sciences industry, including business development and strategy, general management, drug development, and commercial strategy.  He succeeds Kathleen M. Metters, Ph.D., who currently serves as senior advisor to the company.

[Read More]

Labrys Biologics secures $31M financing, acquires antibody for chronic migraine from Pfizer

Friday, January 4, 2013

Labrys Biologics, a development stage biotechnology company focused on chronic migraines, has completed a $31 million Series A financing from four leading venture capital firms: venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a phase II ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P. James has been appointed president and CEO.

[Read More]

Amgen to acquire KAI Pharmaceuticals

Tuesday, April 10, 2012

Amgen of Thousand Oaks, Calif., has agreed to acquire South San Francisco-based KAI Pharmaceuticals, a privately held pharmaceutical company.  KAI’s lead product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis. Amgen will acquire worldwide rights, excluding Japan, to KAI-4169.

[Read More]